S9624 Ifosfamide in Treating Patients With Meningeal Tumors

• Status: Terminated
• Trial end date: 2004-01-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Southwest Oncology Group
• Collaborators: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
• Treatments: Ifosfamide; Isophosphamide mustard

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven recurrent or unresectable:

• Malignant meningioma

• Intracranial hemangiopericytoma

• Primary central nervous system sarcoma, including:

• Fibrosarcoma

• Rhabdomyosarcoma

• Chondrosarcoma

• Leiomyosarcoma

• Measurable or evaluable disease on CT or MRI scan

• Persistent disease following biopsy or incomplete resection OR

• Recurrent disease following complete resection

• No benign meningioma

• No prior or current systemic sarcoma

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• SWOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• WBC at least 3,000/mm^3

• Absolute granulocyte count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

Hepatic:

• Not specified

Renal:

• Creatinine no greater than 2.0 mg/dL

Cardiovascular:

• No myocardial infarction within the past 3 months

• No active angina

• No unstable heart rhythms

• No congestive heart failure

Other:

• HIV negative

• No allergy to study drugs

• No serious concurrent medical or psychiatric illness

• No uncontrolled peptic ulcer disease

• No prior malignancy within past 5 years except adequately treated:

• Basal or squamous cell carcinoma of the skin

• Carcinoma in situ of the cervix

• Not pregnant or nursing

• Effective contraception required of fertile patients

PRIOR CONCURRENT THERAPY:

• Recovered from toxic effects of prior therapy and/or from postoperative complications

Biologic therapy:

• Not specified

Chemotherapy:

• No prior ifosfamide

• No other concurrent chemotherapy

Endocrine therapy:

• No concurrent hormonal therapy (except estrogen replacement therapy)

• Corticosteroids allowed if dose is stable or decreasing

Radiotherapy:

• At least 4 weeks since prior radiotherapy

• Progressive disease following radiation required

• No concurrent radiotherapy

Surgery:

• See Disease Characteristics